Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer
The FDA fully approves Eli Lilly's Inluriyo and Verzenio combination for advanced breast cancer, doubling progression-free survival.
Share
Why It Matters
Eli Lilly got official FDA approval for a new breast cancer medicine. When a medicine works better and helps patients live longer, it shows the company is doing its job well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.